Upgrades, downgrades, and outlook changes from major analysts.
Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.
3,519 total articles
BofA Securities downgraded Sanofi from Buy to Neutral and cut its price target to $54.50 from $59.16, citing investor unease around an incoming leadership transition and limited near-term pipeline catalysts. The move follows Sanofi's announcement that CEO Paul Hudson will depart on February 17 and that Belén Garijo, formerly of Merck KGaA, will tak…
BMO Capital reiterated its Outperform rating and maintained a $360.00 price target on McDonald’s following the company’s fourth-quarter 2025 results. McDonald’s reported adjusted Q4 EPS of $3.12, topped revenue expectations, and posted robust comparable-sales performance, particularly in the U.S. While BMO expects modest downward pressure on consen…
BMO Capital cut its price target on Cognizant Technology Solutions to $83 from $96 while retaining a Market Perform rating. The firm pointed to artificial intelligence-related ripple effects across the technology sector and limited upside for valuation multiples among IT services providers, even as it expects Cognizant to meet its CY26 guidance and…
TD Cowen launched coverage of D-Wave Quantum Inc. (QBTS) with a Buy rating, highlighting the company’s commanding position in quantum annealing hardware and strong financial metrics. The research note emphasized high gross margins, rapid revenue growth, a robust balance sheet and recent uptake in system usage and enterprise contracts, while acknowl…
Citizens reduced its price target on Unity Software (U) to $37.00 from $50.00 while retaining a Market Outperform rating after the company's fourth-quarter 2025 results. Unity beat the high end of its Q4 guidance on both revenue and EBITDA, but gave Q1 2026 guidance that fell below consensus on both measures. Citizens pointed to product and operati…
Citizens reduced its 12-month price target on Vertex Inc. (VERX) to $25 from $37 while keeping a Market Outperform rating, citing concerns about the company's pace of product innovation and the need to accelerate AI adoption internally. The stock trades near its 52-week low amid a steep one-year decline. Recent quarterly results beat modest expecta…
Citizens lowered its price target on Shopify to $160 from $200 while retaining a Market Outperform rating after the company delivered solid fourth-quarter 2025 results. Shopify showed 29% year-over-year GMV growth excluding foreign exchange, GAAP operating margin expansion to 17.2%, and revenue of $11.56 billion over the last twelve months. Analyst…
Citizens has kept its Market Outperform rating on Terawulf Inc. (NASDAQ:WULF) and maintained a $22.00 price target, implying roughly 37% upside from the prevailing share price. The firm pointed to Terawulf's strategy of converting upstate New York sites into hyperscale data centers with lower power costs, recent high-performance computing agreement…
Citizens has reiterated a Market Outperform rating on CoreWeave and assigned a $180 price target, implying roughly 90% upside from the stock's recent price. The firm highlights CoreWeave's leadership in GPU-as-a-Service, sizable revenue backlog and rapid top-line growth while noting risks tied to pricing, customer concentration and leverage. Other …
Citizens lowered its price objective on Pegasystems to $58 from $78 while retaining a Market Outperform rating after the company’s fourth-quarter 2025 results. Pegasystems beat consensus on revenue and non-GAAP EPS, and reported rising annual contract value and stronger-than-expected free cash flow, but a modest slowdown in constant-currency growth…
Citizens has reaffirmed its Market Outperform rating on Applied Blockchain Inc. (APLD) and kept a $40.00 price target, pointing to substantial upside driven by a 4.3GW active development pipeline and fully leased capacity at the North Ellen (Polaris Forge 1) campus. Key leases with CoreWeave and a 200MW agreement with an investment-grade hyperscale…
Citizens has retained its Market Outperform rating on Galaxy Digital (GLXY) and left its $60 price target intact, implying nearly 200% upside from the current share price of $20.39. The firm emphasized Galaxy's expanding position in high-performance computing (HPC) through its Helios campus in West Texas, where an 800MW contract with CoreWeave is s…
Citizens reaffirmed a Market Outperform rating and a $30.00 price target on Fermi Inc. (NASDAQ: FRMI) following a site visit to the company’s planned 11GW data center complex. The target implies more than 215% upside from the current share price of $9.52 and aligns with a bullish analyst consensus with targets between $20 and $37. Citizens highligh…
Citizens reiterated its Market Outperform rating and $400 price target on AeroVironment (NASDAQ:AVAV), citing robust defense funding trends, the strategic BlueHalo merger and growing international opportunities. The firm noted the company’s rapid revenue growth and mass-production experience, while analysts expect profitability and continued sales …
Citizens has reaffirmed a Market Outperform rating on Equinix with a $1,200 price objective after the data center operator released quarterly results. The target implies nearly 40% upside from the current share price of $867.52 even as the stock trades at a high P/E of 78.88. Citizens points to accelerating capacity deployments and an expanding bac…
Goldman Sachs downgraded National Bank of Greece from Buy to Neutral even as it increased its target price to EUR16.75 from EUR15.10. The bank reported a 19.0% CET1 ratio at the end of the third quarter of 2025 and holds around EUR1.9 billion in excess capital, roughly 14% of its market capitalization. Analysts expect the bank to remain profitable …
Citizens has retained a Market Outperform rating and a $60.00 price target on AtriCure Inc. (NASDAQ: ATRC) ahead of the company’s full fourth-quarter 2025 results. The call follows Edwards Lifesciences’ announcement of plans to introduce a surgical Left Atrial Appendage Closure (LAAC) technology later this year, an update that briefly pushed AtriCu…
Mizuho upgraded Shopify (NASDAQ: SHOP) from Neutral to Outperform while maintaining a $150 price target, highlighting artificial intelligence as a structural tailwind and pointing to strong recent execution. The stock trades near $118.71 after a 6.72% one-week gain but remains down 26.25% year-to-date. Recent fourth-quarter 2025 results beat expect…
Raymond James upgraded Oscar Health Inc. from Market Perform to Outperform and set a $18 price target, citing attractive relative valuation and expected margin recovery across the ACA exchange market. The firm projects modest positive EBIT margins in 2026 and further improvement in 2027, even as Oscar reported mixed fourth-quarter financials that f…
William Blair has upgraded Fastly Inc. (NASDAQ: FSLY) from Market Perform to Outperform, highlighting the company’s positioning to capture increasing traffic driven by large language models (LLMs) and agentic AI. The upgrade follows a quarter William Blair called a "stellar quarter," stronger-than-expected fourth-quarter 2025 results and recent upw…
JPMorgan upgraded LuxExperience (NYSE:LUXE) from Neutral to Overweight and raised its price target to $14 from $9 following management meetings in New York City. The bank substantially increased its adjusted EBITDA projections for fiscal years 2026 and 2027 and cited management confirmation that the company remains on track for targeted EBITDA marg…
Morgan Stanley raised its rating on Ermenegildo Zegna Group (ZGN) from Underweight to Equalweight and set a $11.00 price target following stronger-than-expected preliminary fourth-quarter sales, notably in the Zegna brand's direct-to-consumer channel. The company also reported Q4 and full-year 2025 revenue gains and drew a separate upgrade from UBS…
HSBC has downgraded BP Plc from Hold to Reduce and reduced its price target to GBP4.30 from GBP4.75, flagging roughly 9% downside versus the current share price. The bank says BP's strategic moves - including faster deleveraging and a rebuilt upstream pipeline - are appropriate but will take years to materially alter the company’s outlook. HSBC hig…
Wells Fargo downgraded Inspire Medical Systems (INSP) from Overweight to Equal Weight and reduced its price target to $70 from $145, citing persistent uncertainty around physician reimbursement. The new target sits near the stock's recent trading level, after INSP shares fell sharply over the past year. Separate analyst action from Baird echoed rei…
Rothschild Redburn downgraded Arcellx Inc. (ACLX) from Buy to Neutral and reduced its price target to $82 from $113, pointing to rising competition in larger treatment markets across earlier multiple myeloma lines as the main factor. The firm kept a constructive view of Arcellx's anito-cel in late-line disease based on clinical data and a physician…
